Gilead’s subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa & Harvoni for the Treatment of Chronic Hepatitis C

 Gilead’s subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa & Harvoni for the Treatment of Chronic Hepatitis C

Gilead’s subsidiary Asegua Therapeutics Plans to Launch Authorized Generic Versions in the US of Epclusa & Harvoni for the Treatment of Chronic Hepatitis C

Shots:

  • Generic of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg) will be launched at a list price of $24,000 for common course of therapy and will be available from Jan, 2019
  • The authorized generics will offer saving in Medicare Part D setting for up to $2,500 in out-of-pocket costs per course of therapy and also to state managed Medicaid plans gaining no benefit from negotiating rebates, opening an easy access for medications
  • The goal is to lower the list price of Epclusa and Harvoni, with involvement of an alternative of lower-price for HCV medications

Click here to read full press release/ article | Ref: Gilead | Image: The Street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post